Latest News and Press Releases

PHOENIX, Sept. 04, 2025 (GLOBE NEWSWIRE) -- A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr. Stephen Johnston and Kristina Johnston, announced today that it has awarded...

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Persephoni BioSciences LLC ("Persephoni"), a leading global life sciences venture studio, is proud to announce a $1.5 million...

Burlingame, CA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The Global Vitamin D Therapy Market is estimated to be valued at USD 2.64 Bn in 2025 and is expected to reach USD 5.62 Bn by 2032, exhibiting a...

Kailera Therapeutics announced participation in upcoming investor conferences.

Austin, TX, USA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “US Personalized Medicine Market Size, Trends and Insights By Product...

Hengrui and Kailera announced positive topline data from Hengrui’s Phase 3 clinical trial of HRS9531, a novel dual GLP-1/GIP receptor agonist, in obesity.

60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) EO2463 plus R2 was well tolerated in patients with follicular and marginal zone...

Hengrui Pharma and Kailera today announced the presentation of six abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA).

Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics Clearmind Medicine Inc. (Nasdaq:...

Lilly taps Juvena's AI platform, the first to map the therapeutic potential of secreted proteins, to discover treatments that improve muscle health.